LEXINGTON, Mass., Feb. 20, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced findings from a post hoc analysis of the eNRGy trial (NCT02912949) evaluating treatment beyond progression ...
Renal cell carcinoma (RCC) is a biologically heterogeneous and often unpredictable tumor, and its management requires a finely tuned balance between evidence, experience, and individualized judgment.
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results